Compare Crispr Therapeutics AG (CRSP) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Alliant Energy Corporation — how do they compare? Crispr Therapeutics AG trades at $50.45 (market cap $4.97B), while Alliant Energy Corporation trades at $75.57 (market cap $19.71B). The key difference: Alliant Energy Corporation is far larger — about 4× Crispr Therapeutics AG's market cap, and Alliant Energy Corporation pays a 2.73% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | LNT | |
|---|---|---|
Market Cap | $4.97B | $19.71B |
Sector | Health | Utilities |
52-Week High | $76.78 | $78.03 |
52-Week Low | $44.34 | $61.85 |
Enterprise Value | $3.32B | $31.43B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Alliant Energy (LNT) trades at $76.63, up 0.3% today, near the consensus price target of $76.50. The stock shows a bullish technical trend with strong moving average signals. Recent earnings have mostly beaten estimates, with Q1 2026 EPS of $0.82 exceeding expectations. The company's $13.4 billion clean energy investment plan aims to capitalize on data center demand and drive 5-7% annual earnings growth, supported by rising operating cash flow and a solid 18.58% net income margin.
LNT presents a balanced opportunity with steady utility earnings and growth initiatives, but faces risks from high capital expenditure and rising debt levels. Analyst sentiment is positive with a 52% buy rating, though the stock's valuation multiples like a P/E of 24.1 suggest limited near-term upside without significant earnings acceleration. Regulatory approvals and execution on its investment plan are critical for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
